Search results
Showing 91 to 103 of 103 results for rituximab
This guidance has been updated and replaced by NICE technology appraisal guidance 195.
Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]
Discontinued [GID-TA10869]
Discontinued [GID-TA10308]
Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]
Discontinued [GID-TA10480]
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)
This guidance has been updated and replaced by NICE technology appraisal guidance 629.
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.
The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma (TA37)
This guidance has been updated and replaced by NICE technology appraisal guidance 137.
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
Discontinued [GID-TAG393]
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
More than 1,000 people each year will benefit from NICE's recommendation.